Vigil Neuroscience (VIGL) Stock Forecast, Price Target & Predictions
VIGL Stock Forecast
Vigil Neuroscience stock forecast is as follows: an average price target of $11.00 (represents a 184.24% upside from VIGL’s last price of $3.87) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
VIGL Price Target
VIGL Analyst Ratings
Vigil Neuroscience Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 15, 2024 | Paul Matteis | Stifel Nicolaus | $11.00 | $3.12 | 252.02% | 184.24% |
Vigil Neuroscience Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 1 |
Avg Price Target | - | $11.00 | $11.00 |
Last Closing Price | $3.87 | $3.87 | $3.87 |
Upside/Downside | -100.00% | 184.24% | 184.24% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 14, 2024 | Guggenheim | Buy | Buy | Hold |
Jun 28, 2024 | Wedbush | Outperform | Outperform | Hold |
Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Vigil Neuroscience Financial Forecast
Vigil Neuroscience Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-19.58M | $-19.16M | $-18.74M | $-21.03M | $-22.85M | $-22.10M | $-22.33M |
High Forecast | $-19.58M | $-19.16M | $-18.74M | $-21.03M | $-22.85M | $-18.48M | $-22.33M |
Low Forecast | $-19.58M | $-19.16M | $-18.74M | $-21.03M | $-22.85M | $-26.52M | $-22.33M |
Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.48 | $-0.47 | $-0.46 | $-0.52 | $-0.56 | $-0.54 | $-0.55 |
High Forecast | $-0.48 | $-0.47 | $-0.46 | $-0.52 | $-0.56 | $-0.46 | $-0.55 |
Low Forecast | $-0.48 | $-0.47 | $-0.46 | $-0.52 | $-0.56 | $-0.65 | $-0.55 |
Surprise % | - | - | - | - | - | - | - |
Vigil Neuroscience Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
VIGL | Vigil Neuroscience | $3.87 | $11.00 | 184.24% | Buy |
PRTC | PureTech Health | $20.83 | $57.00 | 173.64% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
THRD | Third Harmonic Bio | $12.11 | $16.15 | 33.36% | Buy |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
TRDA | Entrada Therapeutics | $17.77 | $18.00 | 1.29% | Buy |
VIGL Forecast FAQ
Is Vigil Neuroscience a good buy?
Yes, according to 3 Wall Street analysts, Vigil Neuroscience (VIGL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of VIGL's total ratings.
What is VIGL's price target?
Vigil Neuroscience (VIGL) average price target is $11 with a range of $11 to $11, implying a 184.24% from its last price of $3.87. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vigil Neuroscience stock go up soon?
According to Wall Street analysts' prediction for VIGL stock, the company can go up by 184.24% (from the last price of $3.87 to the average price target of $11), up by 184.24% based on the highest stock price target, and up by 184.24% based on the lowest stock price target.
Can Vigil Neuroscience stock reach $6?
VIGL's average twelve months analyst stock price target of $11 supports the claim that Vigil Neuroscience can reach $6 in the near future.
What are Vigil Neuroscience's analysts' financial forecasts?
Vigil Neuroscience's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-67.278M (high $-63.662M, low $-71.697M), average SG&A $0 (high $0, low $0), and average EPS is $-1.659 (high $-1.569, low $-1.767). VIGL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-78.518M (high $-78.518M, low $-78.518M), average SG&A $0 (high $0, low $0), and average EPS is $-1.936 (high $-1.936, low $-1.936).